Skip to content
Search

Latest Stories

'UK Covid-19 variant has significantly higher death rate'

A highly infectious variant of Covid-19 that has spread around the world since it was first discovered in Britain late last year is between 30 per cent and 100 per cent more deadly than previous strains, researchers said today (March 10).

In a study that compared death rates among people in Britain infected with the new SARS-CoV-2 variant, known as B.1.1.7, against those infected with other strains, scientists said the new variant had ‘significantly higher’ mortality.


The B.1.1.7 variant was first detected in Britain in September 2020, and has since been found in more than 100 countries.

It has 23 mutations in its genetic code – a relatively high number of changes – and some of these have made it far more able to spread. UK scientists say it is about 40-70 per cent more transmissible than previously dominant circulating coronavirus variants.

In the UK study, published in the British Medical Journal today, infection with the new variant led to 227 deaths in a sample of 54,906 Covid-19 patients, compared with 141 among the same number of patients infected with other variants.

“Coupled with its ability to spread rapidly, this makes B.1.1.7 a threat that should be taken seriously,” said Robert Challen, a researcher at Exeter University who co-led the research.

Independent experts said this study’s findings add to previous preliminary evidence linking infection with the B.1.1.7 virus variant with an increased risk of dying from Covid-19.

Initial findings from the study were presented to the UK government earlier this year, along with other research, by experts on its New and Emerging Respiratory Virus Threats Advisory Group, or NERVTAG, panel.

Lawrence Young, a virologist and professor of molecular oncology at Warwick University, said the precise mechanisms behind the higher death rate of the B.1.1.7 variant were still not clear, but “could be related to higher levels of virus replication as well as increased transmissibility”.

He warned that the UK variant was likely fuelling a recent surge in infections across Europe.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less